Skip to main content
Schott Pharma logo

Schott Pharma — Investor Relations & Filings

Ticker · 1SXP ISIN · DE000A3ENQ51 LEI · 529900TU48UE99NHEY88 F Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-06-04 Regulatory Filings
Country DE Germany
Listing F 1SXP

About Schott Pharma

https://www.schott-pharma.com/en

Schott Pharma is a developer and manufacturer of drug containment solutions and delivery systems for injectable drugs. Serving the pharmaceutical and biotech industries, its portfolio includes prefillable syringes, cartridges, vials, and ampoules. The company provides scientifically proven products designed for the safe storage and administration of medications. Beyond individual components, Schott Pharma offers complete, compatible systems and a range of services, including analytical, development, fill-and-finish, and regulatory support. This integrated approach supports clients from clinical trials through to commercialization, ensuring compatibility across the entire pharma value chain.

Recent filings

Filing Released Lang Actions
SCHOTT Pharma invests in sterile cartridge production in Hungary
Regulatory Filings Classification · 1% confidence The document is a press release dated June 4, 2025, announcing a significant capital investment (over EUR 100 million) by SCHOTT Pharma to expand sterile cartridge production capacity in Hungary. It details business strategy, job creation, and site expansion. This type of announcement, focusing on major corporate investment, expansion, and financing activities, aligns best with the 'Capital/Financing Update' category. It is not an official regulatory report (like 10-K or IR), nor is it a transcript (CT) or a dividend notice (DIV). It is a corporate news item detailing a major capital expenditure and expansion plan, making 'CAP' the most appropriate classification.
2025-06-04 English
Half-yearly financial report 2024/2025
Interim / Quarterly Report Classification · 1% confidence The document is a 'Half-Year Financial Report 2025' for the period ending March 31, 2025. It contains comprehensive financial statements, including the Consolidated Statement of Income, Statement of Financial Position, and Statement of Cash Flows, along with an Interim Group Management Report. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-05-16 English
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
Earnings Release Classification · 1% confidence The document explicitly states it is announcing the results for the 'second quarter of the fiscal year 2025' and includes detailed financial tables for 'Q2 2025' and 'H1 2025'. The key phrase used is 'Half Year Report/Half Year Results' in the metadata section, and the text confirms the publication of these results. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year, which is classified as an Interim / Quarterly Report (IR). It is not a brief announcement of a report (RPA/RNS) because it contains the full results and detailed tables, nor is it the Annual Report (10-K). Q2 2025
2025-05-15 English
Presentation H1 2025
Investor Presentation Classification · 1% confidence The document is explicitly titled 'Q2 2025 - Results presentation' and contains detailed financial figures (Revenue, EBITDA), strategic updates, and forward-looking statements typical of an earnings presentation. It covers a specific fiscal period (Q2 2025) and includes management commentary (CEO/CFO sections). This content strongly aligns with an Investor Presentation (IP), which often accompanies or is the presentation used during an Earnings Release (ER) call. Since it is a structured presentation deck detailing results and strategy, 'Investor Presentation' (IP) is the most accurate classification over a simple 'Earnings Release' (ER) announcement, which is usually just a press release summary. The document is not a full regulatory report like a 10-K or IR.
2025-05-15 English
SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla
M&A Activity Classification · 1% confidence The document is a news release dated May 6, 2025, detailing a strategic investment and partnership involving SCHOTT Pharma, Serum Institute of India (SII), and TPG. It announces the acquisition of a stake in the SCHOTT Poonawalla joint venture. This type of announcement, which details significant corporate transactions like investments, M&A activity, or major strategic shifts, is typically classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital change (SHA/CAP), and it is a news release format disseminated via EQS News, the most appropriate category is the general regulatory/corporate announcement fallback, RNS, unless a more specific category fits. It is not a merger/takeover (TAR) but a strategic investment/stake sale. Given the nature of the announcement (a significant corporate transaction update released as news), RNS (Regulatory Filings/General Announcement) is the best fit among the provided options, as it is not a formal financial report or a specific management/board change.
2025-05-06 English
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations
Earnings Release Classification · 1% confidence The document is dated April 10, 2025, and explicitly discusses 'Preliminary Q2 2025 figures' including sales, EBITDA, and margin expectations for the second quarter ending March 31, 2025. It provides key financial highlights that exceed market consensus and states that the detailed figures will be published later (May 15, 2025). This content structure—a brief, preliminary announcement of key quarterly results—perfectly matches the definition of an Earnings Release (ER). It is not the comprehensive Interim Report (IR) itself, nor is it a full transcript (CT) or a formal Annual Report (10-K). Q2 2025
2025-04-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.